Blandine Mondésert

Blandine Mondésert

Auto-generated profile, based on publicly available information

Blandine Mondésert

Department of Electrophysiology, Montreal Heart Institute, University of Montreal, Montreal, QC, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
PKPaul Khairy
Paul Khairy
MSMichael J Silka
Michael J Silka
JMJeremy P Moore
Jeremy P Moore
JDJames A DiNardo
James A DiNardo
JVJim T Vehmeijer
Jim T Vehmeijer
MLMagalie Ladouceur
Magalie Ladouceur
Sudden cardiac death (SCD) accounts for up to 25% of deaths in patients with congenital heart disease (CHD). To date, research has largely been driven by observational studies and real-world experience. Drawbacks include varying definitions, incomplete taxonomy that considers SCD as a unitary diagnosis as opposed to a terminal event with diverse causes, inconsistent outcome ascertainment, and limited data granularity. Notwithstanding these constraints, identified higher-risk substrates include tetralogy of Fallot, transposition of the great arteries, cyanotic heart disease, Ebstein anomaly, and Fontan circulation. Without autopsies, it is often impossible to distinguish SCD from non-cardiac sudden deaths. Asystole and pulseless electrical activity account for a high proportion of SCDs, particularly in patients with heart failure. High-quality cardiopulmonary resuscitation is essential to improve outcomes. Pulmonary hypertension and CHD complexity are associated with lower likelihood of successful resuscitation. Risk stratification for primary prevention implantable cardioverter-defibrillators (ICDs) should consider the probability of SCD due to a shockable rhythm, competing causes of mortality, complications of ICD therapy, and associated costs. Risk scores to better estimate probabilities of SCD and CHD-specific guidelines and consensus-based recommendations have been proposed. The subcutaneous ICD has emerged as an attractive alternative to transvenous systems in those with vascular access limitations, prior device infections, intra-cardiac shunts, or a Fontan circulation. Further improving SCD-related outcomes will require a multidimensional approach to research that addresses disease processes and triggers, taxonomy to better reflect underlying pathophysiology, high-risk features, early warning signs, access to high-quality cardiopulmonary resuscitation and specialized care, and preventive therapies tailored to underlying mechanisms.

1 November 2015 in HeartRhythm Case Reports
Verified
Journal Article
Open access
BMBlandine Mondésert
Blandine Mondésert
MDMarc Dubuc
Marc Dubuc
PKPaul Khairy
Paul Khairy
PGPeter G. Guerra
Peter G. Guerra
GGGilbert Gosselin
Gilbert Gosselin
BTBernard Thibault
Bernard Thibault

1 July 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
VWVictor Waldmann
Victor Waldmann
MLMikael Laredo
Mikael Laredo
SASylvia Abadir
Sylvia Abadir
BMBlandine Mondésert
Blandine Mondésert
PKPaul Khairy
Paul Khairy

31 March 2025 in EP Europace
Verified
Journal Article
Open access
JDJean Claude Deharo
Jean Claude Deharo
JDJulien Dreyfus
Julien Dreyfus
MBMaria-Grazia Bongiorni
Maria-Grazia Bongiorni
HBHaran Burri
Haran Burri
PDPascal Defaye
Pascal Defaye
ZWZachary Whinnett
Zachary Whinnett
Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.

28 November 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
BSBruce S. Stambler
Bruce S. Stambler
FPFrancis Plat
Francis Plat
PSPhilip t Sager
Philip t Sager
SSSilvia Shardonofsky
Silvia Shardonofsky
DWDouglas Wight
Douglas Wight
ACA. John Camm
A. John Camm
Background: Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal–dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT. Methods: NODE-301, a phase 3, multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of etripamil nasal spray administered, unsupervised in patients with symptomatic sustained PSVT. After a medically supervised etripamil test dose while in sinus rhythm, patients were randomized 2:1 to receive etripamil 70 mg or placebo. When PSVT symptoms developed, patients applied a cardiac monitor and attempted a vagal maneuver; if symptoms persisted, they self-administered blinded treatment. An independent Adjudication Committee reviewed continuous electrocardiogram recordings. The primary efficacy endpoint was termination of adjudicated PSVT within 5 hours after study drug administration. Results: NODE-301 accrued 156 positively adjudicated PSVT events treated with etripamil (n=107) or placebo (n=49). The hazard ratio for the primary endpoint, time-to-conversion to sinus rhythm during the 5-hour observation period, was 1.086 (95% CI, 0.726–1.623; P =0.12). In predefined sensitivity analyses, etripamil effects (compared with placebo) occurred at 3, 5, 10, 20, and 30 minutes ( P <0.05). For example, at 30 minutes, there was a 53.7% of SVT conversion in the treatment arm compared to 34.7% in the placebo arm (hazard ratio, 1.87 [95% CI, 1.09–3.22]; P =0.02). Etripamil was well tolerated; adverse events were mainly related to transient nasal discomfort and congestion (19.6% and 8.0%, respectively, of randomized treatment-emergent adverse events. Conclusions: Although the primary 5-hour efficacy endpoint was not met, analyses at earlier time points indicated an etripamil treatment effect in terminating PSVT. Etripamil self-administration during PSVT was safe and well tolerated. These results support continued clinical development of etripamil nasal spray for self-administration during PSVT in a medically unsupervised setting. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03464019.

1 February 2018 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
JGJean-Baptiste Gourraud
Jean-Baptiste Gourraud
MCMarie-A Chaix
Marie-A Chaix
ASAzadeh Shohoudi
Azadeh Shohoudi
PPPierre Pagé
Pierre Pagé
MDMarc Dubuc
Marc Dubuc
BMBlandine Mondésert
Blandine Mondésert
Background: Safety and feasibility data on transvenous lead extraction (TLE) in the challenging population of adults with congenital heart disease (A-CHD) are limited. Herein, we report the results of TLE in A-CHD during a 20-year period. Methods and Results: All consecutive TLE procedures in A-CHD were included in a monocentric prospective registry from 1996. A total of 121 leads were extracted in 49 A-CHD (median age, 38 years; 51% men) during 71 TLE procedures. Twenty-four (49%) patients had transposition of the great arteries. Main indications for extraction were infection in 34 (48%) and lead failure in 22 (31%). A laser sheath was required for 56 (46%) leads and a femoral approach for 10 (8%). Complete TLE was achieved for 111 leads (92%). In multivariable analysis, lead duration (odds ratio, 1.02; 95% confidence interval, 1.00–1.04; P <0.01) and number of previous cardiac surgeries (odds ratio, 2.65; 95% confidence interval, 1.52–4.67; P <0.01) were predictive of TLE failure. No perioperative death or pericardial effusion was observed. Subpulmonary atrioventricular valve regurgitation increased in 8 patients (5 with transposition of the great arteries) and was independently associated with an implantable cardioverter defibrillator lead (odds ratio, 9.69; 95% confidence interval, 1.31–71.64; P =0.03) and valvular vegetation (odds ratio, 7.29; 95% confidence interval, 1.32–40.51; P =0.02). After a median of 54 (19–134) months of follow-up after the first TLE, 3 deaths occurred independently from lead management. Conclusions: Despite complex anatomic issues, TLE can be achieved successfully in most A-CHD using advanced extraction techniques. Subpulmonary atrioventricular valve regurgitation is a prevalent complication, particularly in patients with transposition of the great arteries.